RESUMO
Anti-platelet agents play a central part in the treatment and prevention of acute thrombotic events. Discriminating animal models are needed for the development of novel agents. The chacma baboon has been extensively used as a model to evaluate anti-platelet agents. However, limited data exist to prove the translatability of this species to humans. We aimed to determine the suitability of the chacma baboon in preclinical human targeted GPIIb/IIIa, GPIbα and P2Y12 studies. Light-transmission platelet aggregometry (LTA), whole blood impedance aggregometry, receptor number quantification and genomic DNA sequencing were performed. Baboon ADP and arachidonic acid-induced LTA aggregation results differed significantly from human values, even at increased concentrations. LTA ristocetin-induced agglutination was comparable between species, but baboon platelets needed twice the concentration of ristocetin to elicit a similar response. Citrated baboon blood had significantly less aggregation than humans when evaluated with impedance aggregometry. However, hirudinised baboon whole blood gave similar aggregation as humans at the same agonist concentrations. GPIIb, GPIIIa and GPIbα numbers were significantly more on the baboon platelets. None of the amino acids deemed vital for receptor function, ligand binding or receptor inhibition, were radically different between the species. However, a conservative change in a calcium-binding region of GPIIb may render the baboon platelets more sensitive to calcium-binding agents. The chacma baboon may be used for the evaluation of human-targeted GPIIb/IIIa-, GPIbα- and P2Y12-inhibiting agents. However, the best anticoagulant, optimal agonist concentrations, increase in receptor number and sequence differences must be considered for any future studies.
Assuntos
Plaquetas/efeitos dos fármacos , Plaquetas/metabolismo , Inibidores da Agregação Plaquetária/farmacologia , Glicoproteínas da Membrana de Plaquetas/metabolismo , Receptores de Superfície Celular/metabolismo , Difosfato de Adenosina/farmacologia , Sequência de Aminoácidos , Substituição de Aminoácidos , Animais , Ácido Araquidônico/farmacologia , Avaliação Pré-Clínica de Medicamentos , Citometria de Fluxo , Humanos , Masculino , Papio ursinus , Agregação Plaquetária/efeitos dos fármacos , Glicoproteínas da Membrana de Plaquetas/química , Glicoproteínas da Membrana de Plaquetas/genética , Receptores de Superfície Celular/química , Receptores de Superfície Celular/genética , Receptores Purinérgicos P2/química , Receptores Purinérgicos P2/genética , Receptores Purinérgicos P2/metabolismo , Ristocetina/farmacologiaRESUMO
()Epigallocatechin gallate (EGCG) is a major component of green tea. It has been demonstrated that EGCG has an antithrombotic effect by inhibiting platelet aggregation. However, the detailed mechanisms underlying the effects of EGCG remain to be elucidated. The present study examined the effects of EGCG on human platelet activation by various stimulators and the exact underlying mechanisms. EGCG suppressed adenosine diphosphate (ADP)stimulated platelet aggregation dose dependently between 30 and 70 µM. By contrast, EGCG failed to affect platelet aggregation stimulated by collagen, U46619 (a TP agonist) or ristocetin (an activator of GPIb/IX/V). EGCG attenuated the ADPinduced phosphorylation of p38 mitogenactivated protein (MAP) kinase and heat shock protein 27 (HSP27). The ADPstimulated release of plateletderived growth factor (PDGF)AB and the soluble CD40 (sCD40) ligand was inhibited by EGCG. These findings suggest that EGCG selectively inhibits ADPstimulated human platelet activation and that EGCG reduces the release of PDGFAB and the sCD40 ligand due to suppressing HSP27 phosphorylation via p38 MAP kinase.
Assuntos
Difosfato de Adenosina/farmacologia , Catequina/análogos & derivados , Ativação Plaquetária/efeitos dos fármacos , Ácido 15-Hidroxi-11 alfa,9 alfa-(epoximetano)prosta-5,13-dienoico/farmacologia , Ligante de CD40/genética , Ligante de CD40/metabolismo , Catequina/farmacologia , Proteínas de Choque Térmico HSP27/antagonistas & inibidores , Proteínas de Choque Térmico HSP27/genética , Proteínas de Choque Térmico HSP27/metabolismo , Proteínas de Choque Térmico , Humanos , Chaperonas Moleculares , Fosforilação , Agregação Plaquetária/efeitos dos fármacos , Fator de Crescimento Derivado de Plaquetas/genética , Fator de Crescimento Derivado de Plaquetas/metabolismo , Ristocetina/farmacologia , Chá/química , Proteínas Quinases p38 Ativadas por Mitógeno/genética , Proteínas Quinases p38 Ativadas por Mitógeno/metabolismoRESUMO
Epoxyeicosatrienoic acids (EETs) produced by cytochrome P450 (CYP)-dependent epoxidation of arachidonic acid (AA) inhibit thrombocyte adhesion to the vascular wall. Upon dietary omega-3 fatty acid supplementation, EETs are partially replaced by eicosapentaenoic acid (EPA)-derived epoxyeicosatetraenoic acids (EEQs) and docosahexaenoic acid (DHA)-derived epoxydocosapentaenoic acids (EDPs). We hypothesized that the omega-3 epoxy-metabolites may exhibit superior anti-thrombogenic properties compared to their AA-derived counterparts. To test this hypothesis, we analyzed the effects of 11,12-EET, 17,18-EEQ and 19,20-EDP on Ristocetin-induced thrombocyte aggregation (RITA), a process that mimics thrombocyte adhesion to the vascular wall. The eicosanoids were added for 5, 30, or 60 minutes to thrombocyte-rich plasma freshly prepared immediately after blood collection from stringently selected apparently healthy subjects. Thrombocyte aggregation was then induced by Ristocetin (0.75 mg/mL) and assessed by turbidimetric measurements. After 60 minutes of preincubation, all three epoxy-metabolites significantly decreased the rate of RITA. 17,18-EEQ and 19,20-EDP were effective already at 1 µM, whereas 5-fold higher concentrations were required with 11,12-EET. Addition of AUDA, an inhibitor of the soluble epoxide hydrolase, potentiated the effect of 17,18-EEQ resulting in a significant further decrease of the velocity as well as amplitude of the aggregation process. In contrast to their profound effects on RITA, none of the epoxy-metabolites was effective in reducing collagen- or ADP-induced thrombocyte aggregation. These results indicate a highly specific role of CYP-eicosanoids in preventing thromboembolic events and suggest that the formation of 17,18-EEQ and 19,20-EDP may contribute to the anti-thrombotic effects of omega-3 fatty acids.
Assuntos
Antibacterianos/farmacologia , Plaquetas/citologia , Plaquetas/efeitos dos fármacos , Sistema Enzimático do Citocromo P-450/metabolismo , Eicosanoides/metabolismo , Eicosanoides/farmacologia , Ristocetina/farmacologia , Agregação Celular/efeitos dos fármacos , Humanos , Masculino , OxirreduçãoRESUMO
A novel C-type lectin-like protein, dabocetin, was purified from Daboia russellii siamensis venom. On SDS-polyacrylamide gel electrophoresis, it showed a single band with an apparent molecular weight of 28 kDa and two distinct bands with the apparent molecular weights of 15.0 kDa and 14.5 kDa under non-reducing and reducing conditions, respectively. cDNA clones containing the coding sequences for dabocetin alpha and beta subunits were isolated and sequenced. The deduced protein sequences of both subunits were confirmed by N-terminal amino acid sequencing and trypsin-digested peptide mass fingerprinting. Dabocetin did not induce platelet aggregation in platelet-rich plasma. It also had little effect on the platelet aggregation induced by ADP, TMVA or stejnulxin. Whereas, dabocetin inhibited ristocetin-induced platelet agglutination in platelet-rich plasma in a dose-dependent manner with an IC50 value of 0.35 microM. Flow cytometry analysis showed that dabocetin significantly inhibited mAb SZ2 binding to platelet membrane glycoprotein Ib alpha, indicating that platelet membrane glycoprotein Ib is involved in the inhibitory effect of dabocetin on ristocetin-induced platelet agglutination.
Assuntos
Lectinas Tipo C/antagonistas & inibidores , Inibidores da Agregação Plaquetária/farmacologia , Agregação Plaquetária/efeitos dos fármacos , Venenos de Víboras/química , Viperidae , Difosfato de Adenosina/farmacologia , Sequência de Aminoácidos , Animais , Anticorpos Monoclonais/imunologia , Anticorpos Monoclonais/metabolismo , Sequência de Bases , Clonagem Molecular , DNA Complementar/genética , Eletroforese em Gel de Poliacrilamida , Citometria de Fluxo , Concentração Inibidora 50 , Lectinas Tipo C/genética , Lectinas Tipo C/isolamento & purificação , Dados de Sequência Molecular , Peso Molecular , Complexo Glicoproteico GPIb-IX de Plaquetas/antagonistas & inibidores , Ristocetina/farmacologia , Venenos de Víboras/genética , Venenos de Víboras/farmacologiaRESUMO
INTRODUCTION: Platelet adhesion is an initial, crucial and complex event for inhibiting blood loss upon vascular injury. Activation and adhesion of platelets also play a fundamental role in the development of thrombosis. A combination of exposed extracellular matrix proteins in the vascular wall and release of activating compounds from the participating cells activate the platelets. New potent anti-platelet agents are in progress but there is a shortage of methods that measure the concerted action of adhesive surfaces and soluble compounds upon platelet adhesion in vitro. The aim of this work was to develop a method to measure adhesion of platelets in plasma with standard laboratory equipment. METHODS: Platelet-rich plasma from healthy humans was used in studies to optimise the conditions of the present assay. Different proteins were coated in microplate wells and various soluble platelet activators and inhibitors were added to establish the ability of the current method to detect increased as well as decreased platelet adhesion. The amount of platelet adhesion was measured by the reaction between p-nitrophenyl phosphate and the intracellular enzyme acid phosphatase. RESULTS: Adhesion of platelets in plasma to microplate wells coated with albumin, collagen, fibrinogen and activated plasma showed significant surface dependency. The known soluble platelet activators adenosine diphosphate, adrenaline and ristocetin enhanced the levels of adhesion. Available anti-platelet agents such as prostacyclin, forskolin, acetylsalicylic acid and RGD containing peptides caused dose-dependent inhibition of platelet adhesion. DISCUSSION: This report describes a further development of a previously described method and offers the advantage to use platelets in plasma to measure platelet adhesion to protein surfaces. The assay is simple and flexible and is suitable in basic research for screening and characterisation of platelet adhesion responsiveness.
Assuntos
Plaquetas/fisiologia , Plasma/fisiologia , Adesividade Plaquetária , Proteínas/metabolismo , Difosfato de Adenosina/farmacologia , Albuminas/metabolismo , Plaquetas/efeitos dos fármacos , Colágeno/metabolismo , Relação Dose-Resposta a Droga , Avaliação Pré-Clínica de Medicamentos/métodos , Epinefrina/farmacologia , Fibrinogênio/metabolismo , Humanos , Técnicas In Vitro , Concentração Inibidora 50 , Adesividade Plaquetária/efeitos dos fármacos , Inibidores da Agregação Plaquetária/farmacologia , Análise de Regressão , Reprodutibilidade dos Testes , Ristocetina/farmacologiaRESUMO
Platelet aggregation was measured by an optical method in 32 patients with iron-deficiency anemia at the time of diagnosis and after a period of supplementation with iron. Epinephrine- and adenosine diphosphate-induced platelet aggregation were lower in anemic patients than in the controls (p<0.05). After iron-supplementation therapy, these values showed no significant differences. If induced by collagen or ristocetin, platelet aggregation was the same for patients and controls, but increased after treatment of patients (p<0.05). The plasma zinc values did not show significant differences among the subjects included in this study. These results show that iron is involved in the enzymatic systems that regulate platelet aggregation. The exact nature of this interaction is still to be determined.
Assuntos
Anemia Ferropriva/sangue , Ferro/sangue , Ferro/farmacologia , Agregação Plaquetária/efeitos dos fármacos , Anemia Ferropriva/dietoterapia , Colágeno/farmacologia , Suplementos Nutricionais , Feminino , Humanos , Ferro/administração & dosagem , Ferro/uso terapêutico , Masculino , Ristocetina/farmacologia , Zinco/sangueRESUMO
Penicillin binding protein (PBP) 1b of Escherichia coli has both transglycosylase and transpeptidase activities, which are attractive targets for the discovery of new antibacterial agents. A high-throughput assay that detects inhibitors of the PBPs was described previously, but it cannot distinguish them from inhibitors of the MraY, MurG, and lipid pyrophosphorylase. We report on a method that distinguishes inhibitors of both activities of the PBPs from those of the other three enzymes. Radioactive peptidoglycan was synthesized by using E. coli membranes. Following termination of the reaction the products were analyzed in three ways. Wheat germ agglutinin (WGA)-coated scintillation proximity assay (SPA) beads were added to one set, and the same beads together with a detergent were added to a second set. Type A polyethylenimine-coated WGA-coated SPA beads were added to a third set. By comparison of the results of assays run in parallel under the first two conditions, inhibitors of the transpeptidase and transglycosylase could be distinguished from inhibitors of the other enzymes, as the inhibitors of the other enzymes showed similar inhibitory concentrations (IC(50)s) under both conditions but the inhibitors of the PBPs showed insignificant inhibition in the absence of detergent. Furthermore, comparison of the results of assays run under conditions two and three enabled the distinction of transpeptidase inhibitors. Penicillin and other beta-lactams showed insignificant inhibition with type A beads compared with that shown with WGA-coated SPA beads plus detergent. However, inhibitors of the other four enzymes (tunicamycin, nisin, bacitracin, and moenomycin) showed similar IC(50)s under both conditions. We show that the main PBP being measured under these conditions is PBP 1b. This screen can be used to find novel transglycosylase or transpeptidase inhibitors.
Assuntos
Proteínas da Membrana Bacteriana Externa , Proteínas de Bactérias/antagonistas & inibidores , Proteínas de Transporte/antagonistas & inibidores , Avaliação Pré-Clínica de Medicamentos/métodos , Escherichia coli/efeitos dos fármacos , Escherichia coli/enzimologia , Glicosiltransferases/antagonistas & inibidores , Hexosiltransferases/antagonistas & inibidores , Muramilpentapeptídeo Carboxipeptidase/antagonistas & inibidores , Peptidil Transferases/antagonistas & inibidores , Antibacterianos/farmacologia , Proteínas de Bactérias/metabolismo , Proteínas de Transporte/metabolismo , Detergentes/farmacologia , Inibidores Enzimáticos/farmacologia , Glicosiltransferases/metabolismo , Hexosiltransferases/metabolismo , Muramilpentapeptídeo Carboxipeptidase/metabolismo , N-Acetilglucosaminiltransferases/antagonistas & inibidores , Proteínas de Ligação às Penicilinas , Peptidoglicano/biossíntese , Peptidil Transferases/metabolismo , Ristocetina/farmacologia , Transferases/antagonistas & inibidores , Transferases (Outros Grupos de Fosfato Substituídos) , Vancomicina/farmacologia , Aglutininas do Germe de TrigoRESUMO
Although it is known that platelet count is altered in iron deficiency anaemia (IDA), the qualitative extent of this interference is not well documented. In the present study we investigated platelet aggregation (PA) by impedance and optic methods in IDA. Forty-seven patients (plasma group: 16 boys, 9 girls and whole blood group: 11 boys, 11 girls) with IDA and thirty-one healthy children (plasma group: 6 boys, 10 girls and whole blood group: 6 boys, 9 girls) were enrolled into the study. Template bleeding times were measured by the Ivy method in all children. In the control group whole blood count, serum iron levels, bleeding time and PA were determined. After basal PA was determined in the patients and controls, ferrous sulphate was orally administered to the patients at a dose of 6 mg/kg/24 h for three months. Then, PA tests were performed again in the IDA (test group) patients. Ristocetin-induced PA was suppressed in both plasma and whole blood groups. Inhibition by both collagen (p < 0.05) and ristocetin (p < 0.001)-induced PA was determined by the optic method. Similarly in PA measured by the impedance method a suppression to adenosine diphosphate (p < 0.001) and to ristocetin (p < 0.01) was found. However, no significant alteration was observed in the bleeding time. All defective responses were reversed by the iron supplementation therapy. In addition, a significant correlation was found between some parameters of PA and several haematological values. In conclusion, although defective PA responses cannot be clinically demonstrated in patients with IDA, this suppression of PA may be detected by laboratory examination. Therefore, it is advised that care should be taken when using anti-aggregant agents in IDA.
Assuntos
Anemia Ferropriva/fisiopatologia , Agregação Plaquetária , Difosfato de Adenosina/farmacologia , Anemia Ferropriva/sangue , Contagem de Células Sanguíneas , Testes de Coagulação Sanguínea , Criança , Pré-Escolar , Colágeno/farmacologia , Impedância Elétrica , Epinefrina/farmacologia , Índices de Eritrócitos , Feminino , Ferritinas/sangue , Hemoglobinas/metabolismo , Humanos , Lactente , Masculino , Agregação Plaquetária/efeitos dos fármacos , Testes de Função Plaquetária/instrumentação , Testes de Função Plaquetária/métodos , Ristocetina/farmacologia , Análise Espectral , Transferrina/metabolismoRESUMO
Isolated platelet factor 3 (PF3) availability defect has been observed to be a common platelet functional disorder (PFD) in the Department of Haematology, All India Institute of Medical Sciences, New Delhi, India. One hundred and thirty-two patients were diagnosed to have this defect based on the presence of reduced PF3 availability, normal platelet aggregation with ADP, collagen, adrenaline, ristocetin, and arachidonic acid and normal PF3 content. PF3 availability was evaluated by measurement of Russel viper venom time (RVVT) on the patient's platelet-rich plasma (PRP) after incubation with ADP for 20 min. An RVVT value >19.0 s was considered diagnostic of reduced PF3 availability in patients with normal prothrombin and activated partial thromboplastin times. Isolated PF3 availability defect occurred in patients with ages between 2 and 65 yr and had a female preponderance (M:F=1:2). One fifth of the patients had a positive family history of similar mild bleeding diathesis, indicating an autosomal dominant pattern of inheritance. All patients presented with mild bleeding manifestations, the commonest symptom being appearance of recurrent ecchymotic spots. In females, menorrhagia was the commonest symptom. A pilot study was conducted on 45 patients to evaluate the therapeutic role of oral soya bean (50 g/d). The clinical response was evaluated after 3 months. Soya therapy resulted in disappearance of bleeding problems in 5 patients and reduction in frequency and severity of bleeding in 26 patients. A repeat PF3 availability test after 3 months of therapy showed complete correction in 4 and partial correction in 12 patients. It is evident from McNemer's test that both the clinical and the laboratory parameters (PF3 availability) showed a similar response to soya therapy (p>0.05). Pre-soya therapy mean PF3 availability values differ significantly from those after soya therapy (p<0.01). Thus, soya bean appears to have a therapeutic potential in isolated PF3 availability defect.
Assuntos
Transtornos Plaquetários/sangue , Transtornos Plaquetários/tratamento farmacológico , Glycine max/uso terapêutico , Fitoterapia , Fator Plaquetário 3/metabolismo , Difosfato de Adenosina/farmacologia , Adolescente , Agonistas Adrenérgicos/farmacologia , Adulto , Idoso , Ácido Araquidônico/farmacologia , Biomarcadores , Criança , Pré-Escolar , Colágeno/farmacologia , Epinefrina/farmacologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Projetos Piloto , Agregação Plaquetária/efeitos dos fármacos , Ristocetina/farmacologiaRESUMO
Reduced hemostasis and bleeding tendency after cardiopulmonary bypass results from platelet dysfunction induced by the bypass procedure. The causes of this acquired platelet dysfunction are still subject to discussion, although, recently, greater emphasis has been placed on an overstimulated fibrinolytic system as a probable cause. In the first part of this study we assessed the effects of postoperative retransfusion of shed blood on blood loss to patients undergoing cardiopulmonary bypass. We observed that increasing concentrations of fibrinogen degradation products and tissue-type plasminogen activator stimulating activity in shed blood correlated significantly with a higher postoperative bleeding tendency (p < 0.05 for both). We further noted that retransfusion of shed blood increased the total postoperative blood loss by 43% (925 versus 1320 ml, p < 0.05). On the basis of these clinical observations, we hypothesized that the increased bleeding tendency was caused by fibrinolysis. In the second part of this study we collected evidence in support of this hypothesis by an in vitro study, in which we introduced similar (pro)fibrinolytic activity to platelet-rich plasma and measured the influence of this treatment on platelet function indicated by ristocetin agglutination. Tissue-type plasminogen activator and fibrin monomers (tissue-type plasminogen activator stimulator) together induced severe platelet damage, resulting in a decreased ristocetin agglutination response. Therefore, we propose a fibrinolysis-related mechanism for platelet dysfunction during cardiopulmonary bypass, dependent on fibrinolytic factors such as fibrin monomers, D-dimers, and tissue-type plasminogen activator.
Assuntos
Perda Sanguínea Cirúrgica/fisiopatologia , Plaquetas/fisiologia , Transfusão de Sangue Autóloga/efeitos adversos , Ponte de Artéria Coronária/efeitos adversos , Fibrinólise , Ativador de Plasminogênio Tecidual/fisiologia , Plaquetas/efeitos dos fármacos , Ponte Cardiopulmonar/efeitos adversos , Fibrinogênio/metabolismo , Humanos , Pessoa de Meia-Idade , Estudos Prospectivos , Ristocetina/farmacologia , Ativador de Plasminogênio Tecidual/análise , Fator de von Willebrand/farmacologiaRESUMO
Antibacterial activity of eremomycin, a novel glycopeptide antibiotic, against obligate anaerobic Gram-positive++ bacteria was studied. Eremomycin was shown to inhibit the growth of obligate anaerobic Gram-positive++ cocci and bacteria belonging to Clostridium in rather low concentrations and within narrow ranges of the MIC which was indicative of the antibiotic undoubted advantages. The antibacterial activity of eremomycin was 2 times as high as that of vancomycin and 8 times as high as that of ristomycin with respect to Gram-positive++ anaerobic cocci. Pathogenic strains of Clostridium spp. were 2 to 4 times more sensitive to eremomycin than to vancomycin. A significant property of the novel glycopeptide antibiotic was shown to be its capacity for inhibiting the growth of Gram-positive++ aerobic and obligate anaerobic cocci within the same concentration ranges which might be of importance in monotherapy of mixed aerobic and anaerobic infections.
Assuntos
Antibacterianos/farmacologia , Clostridium/efeitos dos fármacos , Glicopeptídeos/farmacologia , Clostridium/crescimento & desenvolvimento , Meios de Cultura , Avaliação Pré-Clínica de Medicamentos , Resistência Microbiana a Medicamentos , Técnicas In Vitro , Testes de Sensibilidade Microbiana , Ristocetina/farmacologia , Vancomicina/farmacologiaRESUMO
The platelet element content was determined by semiquantitative X-ray microanalysis in 6 patients with chronic renal failure. The patients showed a different degree of thrombocytopathy expressed by impaired adhesiveness, epinephrine-induced aggregation and platelet factor 3 availability. The microanalysis indicated significantly increased quantities of phosphorus and copper in patients' platelets. Sodium and zinc showed a decrease in about half of the patients, whereas iron was significantly increased in at least 50% of the patients. Magnesium and potassium did not show any difference from the control. The results of sulfur, chlorine and calcium did not reveal a consistent pattern.
Assuntos
Plaquetas/ultraestrutura , Elementos Químicos/sangue , Falência Renal Crônica/sangue , Ácido Araquidônico , Ácidos Araquidônicos/farmacologia , Colágeno/farmacologia , Cobre/sangue , Microanálise por Sonda Eletrônica/métodos , Epinefrina/farmacologia , Humanos , Ferro/sangue , Fósforo/sangue , Agregação Plaquetária/efeitos dos fármacos , Fator Plaquetário 3/análise , Ristocetina/farmacologia , Sódio/sangue , Zinco/sangueRESUMO
The MICs and MBCs (minimum bactericidal concentration) of 6 antibiotics (benzylpenicillin, oxacillin, cephalothin, ristomycin, erythromycin and lincomycin) for 50 strains of group A streptococci were determined with serial dilutions in a liquid medium (the medium for isolation of streptococci of the I. I. Mechnikov Moscow Research Institute of Vaccines and Sera) followed by volumetric platings on a solid medium (the same medium supplemented with 1.5 per cent agar). The results are discussed in relation to the problem of Streptococci tolerance to the bactericidal effect of the antibiotics.
Assuntos
Antibacterianos/farmacologia , Streptococcus pyogenes/efeitos dos fármacos , Cefalotina/farmacologia , Eritromicina/farmacologia , Lincomicina/farmacologia , Testes de Sensibilidade Microbiana , Oxacilina/farmacologia , Penicilina G/farmacologia , Resistência às Penicilinas , Ristocetina/farmacologiaRESUMO
The fundamental similarity between platelets and muscle, suggested the possiblity of a shared defect in idiopathic scoliosis, a genetic disease with lateral deformity of the spine in which there is an elevation of calicum concentration in muscles and platelets. A variety of platelet tests revealed the following abnormalities: (1) Electron microscopic x-ray analysis and x-ray fluorescence spectrometry showed a 2- to 3-fold increase in calcium and phosphorus in whole cells and in individual dense bodies. (2) Electron microscopy morphometry revealed an increase in electron-opaque bodies in air-dried cells; granules and microtubules were unchanged. There were more large cells and membranous complexes. (3) Aggregations with epinephrine and ADP were depressed in some patients. (4) Proteins (total and contractile) and myosin. ATPase activity in centrifuged fractions of platelets were decreased in the cytosol and increased in the fraction containing membranes and granules. The correlated findings suggest that platelets in idiopathic scoliosis have a mild calcium transport defect related to membrane and/or contractile protein metabolism. This investigation also shows that platelets may be used to advantage in diagnosis and research of muscle diseases.